Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Fund Type: SICAV
  • Objective: Health Care Sector
  • Asset Class: Equity
  • Geographic Focus: International

Bellevue Funds Lux - BB Adamant Biotech

+ Add to Watchlist

BBBIOCB:LX

452.45 CHF

As of 08:36:00 ET on 05/26/2015.

Snapshot for Bellevue Funds Lux - BB Adamant Biotech (BBBIOCB)

Year To Date: +14.23% 3-Month: +6.24% 3-Year: +43.42% 52-Week Range: 269.78 - 490.45
1-Month: -2.86% 1-Year: +71.43% 5-Year: +26.05% Beta vs LUXXX: 0.93

Mutual Fund Chart for BBBIOCB

No chart data available.
  • BBBIOCB:LX 452.45
  • 1M
  • 1Y
Interactive BBBIOCB Chart

Previous Close

No chart data available.
Interactive Chart
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Fund Profile & Information for BBBIOCB

Bellevue Funds (Lux) - BB Adamant Biotech is an open-end investment fund incorporated in Luxembourg. The Fund's objective is long-term capital appreciation. The Fund invests mainly in equities and equity related securities of companies that are directly involved in the biotechnology sector.

Inception Date: 04-02-2009 Telephone: 41-44-267-67-00
Managers: DANIEL KOLLER
Web Site: www.bellevuegroup.com

Fundamentals for BBBIOCB

NAV (on 2015-05-26) 452.45
Assets (M) (on 2015-05-22) 97.34
Fund Leveraged N
Minimum Investment -
Minimum Subsequent Investment -

Dividends for BBBIOCB

No dividends reported

Fees & Expenses for BBBIOCB

Front Load -
Back Load 0.00
Current Mgmt Fee 1.60
Redemption Fee 0.00
12b1 Fee -
Expense Ratio -

Top Fund Holdings for BBBIOCB

Filing Date: 04/30/2015
Name Position Value % of Total
Biogen Inc 20,000 7,478,600 7.731%
Gilead Sciences Inc 72,000 7,236,720 7.481%
Celgene Corp 63,000 6,807,780 7.038%
Amgen Inc 30,866 4,874,050 5.039%
Mylan NV 55,000 3,974,300 4.109%
Vertex Pharmaceuticals Inc 28,500 3,513,480 3.632%
Alexion Pharmaceuticals Inc 20,746 3,510,846 3.629%
Regeneron Pharmaceuticals Inc 7,595 3,474,409 3.592%
Incyte Corp 33,352 3,240,480 3.350%
Medivation Inc 24,300 2,933,982 3.033%

Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil